Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-09-13
2005-09-13
Celsa, Bennett (Department: 1639)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C514S008100, C514S012200, C514S476000, C514S506000, C514S579000, C424S085100, C424S085200, C424S085400
Reexamination Certificate
active
06943148
ABSTRACT:
The present invention relates to amphiphilic drug-oligomer conjugates capable of traversing the blood-brain barrier (“BBB”) and to methods of making and using such conjugates. An amphiphilic drug-oligomer conjugates comprise a therapeutic compound conjugated to an oligomer, wherein the oligomer comprises a lipophilic moiety coupled to a hydrophilic moiety. The conjugates of the invention further comprise therapeutic agents such as proteins, peptides, nucleosides, nucleotides, antiviral agents, antineoplastic agents, antibiotics, etc., and prodrugs, precursors, derivatives and intermediates thereof, chemically coupled to amphiphilic oligomers.
REFERENCES:
patent: 3256153 (1966-06-01), Heimlich
patent: 4003792 (1977-01-01), Mill et al.
patent: 4044196 (1977-08-01), Hüper et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4410547 (1983-10-01), Ueno et al.
patent: 4537878 (1985-08-01), Plotnikoff
patent: 4585754 (1986-04-01), Meisner et al.
patent: 4622392 (1986-11-01), Hong et al.
patent: 4684524 (1987-08-01), Eckenhoff et al.
patent: 4698264 (1987-10-01), Steinke
patent: 4717566 (1988-01-01), Eckenhoff et al.
patent: 4744976 (1988-05-01), Snipes et al.
patent: 4772471 (1988-09-01), Vanlerberghe et al.
patent: 4797288 (1989-01-01), Sharma et al.
patent: 4840799 (1989-06-01), Appelgren et al.
patent: 4849405 (1989-07-01), Ecanow
patent: 4933324 (1990-06-01), Shashoua
patent: 4935246 (1990-06-01), Ahrens
patent: 4939174 (1990-07-01), Shashoua
patent: 4963367 (1990-10-01), Ecanow
patent: 5013556 (1991-05-01), Woodle et al.
patent: 5055300 (1991-10-01), Gupta
patent: 5055304 (1991-10-01), Makino et al.
patent: 5061691 (1991-10-01), Yagi et al.
patent: 5093198 (1992-03-01), Speaker et al.
patent: 5286637 (1994-02-01), Veronese et al.
patent: 5428128 (1995-06-01), Mensi-Fattohi et al.
patent: 5539063 (1996-07-01), Hakimi et al.
patent: 5545719 (1996-08-01), Shashoua et al.
patent: 5559213 (1996-09-01), Hakimi et al.
patent: 5571795 (1996-11-01), Kahne et al.
patent: 5595732 (1997-01-01), Hakini et al.
patent: 5602099 (1997-02-01), Schiller
patent: 5631263 (1997-05-01), Portoghese et al.
patent: 5641861 (1997-06-01), Dooley et al.
patent: 5653987 (1997-08-01), Modi et al.
patent: 5663295 (1997-09-01), Moreau et al.
patent: 5681811 (1997-10-01), Ekwuribe
patent: 5693769 (1997-12-01), Kahne et al.
patent: 5747646 (1998-05-01), Hakimi et al.
patent: 5786447 (1998-07-01), Schiller et al.
patent: 5792834 (1998-08-01), Hakimi et al.
patent: 5932462 (1999-08-01), Harris et al.
patent: 6309633 (2001-10-01), Ekwuribe et al.
patent: WO 93/01802 (1993-02-01), None
STN: Biosequence Searching For the USPTO (May 1996) pp. 30-31.
Sakane, Toshiyasu, et al., “Carboxy-directed Pegylation of Brain-derived Neurotrophic Factor Markedly Reduces Systemic Clearance with Minimal Loss of Biologic Activity,”Pharmaceutical Research,vol. 14, No. 8, pp. 1085-1091, 1997.
Igarashi et al. “Biologically Active Peptides Conjugated with Lecithin for DDS”Proceed. Intern. Symp. Cont. Rel. Bioactiv. Mater.17:367-368 (1990).
Taniguchi et al. “Synthesis of Acyloyl Lysozome and Improvement of its Lymphatic Transport Following Small Intestinal Administration in Rats”Proceed. Intern. Symp. Control. Rel. Bioactiv. Mater.19:104-105 (1992).
Russell-Jones, G.J. “Vitamin B12 Drug Delivery”Proceed. Intern. Symp. Control. Rel. Bioactive. Mater.19:102-103 (1992).
Baudys, M. t al. :Synthesis and Characteristics of Different Glycosylated Derivatives of InsulinProceed. Intern. Symp;. Cont. Rel. Bioactiv. Mater.19:210-211 (1992).
Chien, Y.W.Novel Drug Delivery Systems678-679 Marcell Deffer, Inc., New York (1992).
Santiago et al. “Oral Immunization of Rats with Influenza Virus M Protein (M1) Microspheres”Proceed Intern. Symp. Cont. Rel. Bioactive. Mater.19:116-117 (1992).
Nucci et al. “The Therapeutic Value of Poly(ethylene glycol)—Modified Proteins”Ac. Drug. Del. Rev.6:133-151 (1991).
Abuchowski and Davis “Soluble Polymer-Enzyme Adducts”Enzymes as Drugs,Holcenberg and Wiley (1981).
Akiyama et al. “The Synthesis of New Derivatives of 1-β-D-Arabinofuranosylcytosine” Chem. Pharm. Bull. 26(3):981 (1978).
Zalipsky et al. “Attachment of Drugs to Polyethylene Glycols”Eur. Polym. J.19:121177-1183 (1983).
Anderson et al. “Structure-Activity Relationship Assessment of Conjugated Enkephalins in Centrally Mediated Analgesia”Soc. Neurosci. Abstr.25(1): 180 (1999).
Delgado et al. “The Uses and Properties of PEG-Linked Proteins”.Critical Review in Therapeutic Drug Carrier Systems,9(3, 4):249-304 (1992).
Pardridge, W.M., “Blood-Brain Barrier Peptide Transport and Peptide Drug Delivery to the Brain,” Amer. Chem Soc. 1995: 265-296.
Pardridge, W.M., “CNS Drug Design Based on Principles of Blood-Brain Barrier Transport,” J. Neurochem., 1998, 70 (5): 1781-1792.
Pardridge, W. M., “New Approaches to Drug Delivery Through the Blood-Brain Barrier,” Trends in Biotechnology, 1994: 239-245.
Prokai-Tatrati, K., et al., “Brain-Targeted Delivery of a Leucine-Enkepahlin Analogue by Retrometabolic Design,” J. Med. Chem 39 (24).
Ratner, R. E. et al., “Persistent Cutaneous Insulin Allergy Resulting From High-Molecular Weight Insulin Aggregates,” Diabetes, 1990, 39:. 728-733.
Robbins, D. C. et al., “Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients,” Diabetes, 1987, 36: 838-841.
Saffran, M. et al., “A New Approach to the Oral Administration of Insulin and Other Peptide Drugs,” Science, 1986, 233: 1081-1084.
Sakaeda, T., et al., “Conjugation with L-Glutamic Acid for Brain Drug Delivery,” Proceed. Intern. Symp. Control. Rel. Bioact. Mater., 1966, 23: 607-608.
Shashoua V.E., et al., “γ-Aminobutyric Acid Esters. 1. Synthesis, Brain Uptake, and Pharmacological Studies of Aliphatic and Steroid Esters of γ-Aminobutyric Acid,” J. Med. Chem., 1984, 27 (5): 660-664.
Shashoua, V.E., et al., “N-Docosahexaenoyl, 3 Hydroxytyramine: A Dopaminergic Compound that Penetrates the Blood-Brain Barrier and Suppresses Appetite,” Life Sciences, 58 (16): 1347-1354.
Sim, L., et al., “In vitro Autoradiography of Receptor-Activated G Proteins in Rat Brain by Agonist-stimulated Guanylyl 5′-[γ[35S]thio]-Triphosphate Binding,” Proc. Natl. Acad. Sci., USA, 1995, 92: 7242-7246.
Terasaki, T., et al., “Oligopeptide Drug Delivery to the Brain,” Amer. Chem. Soc. 1995: 297-316.
Tsuzuki, N., et al., “Rabid Communication. Adamantane as a Brain-Directed Drug Carrier for Poorly Absorbed Drug: Antinociceptive Effects of [D-Ala2] Leu-Enkephalin Derivatives Conjugated with the 1-Adamantane Moiety,” Biochemical Pharmacology, 1991, 41 (4): R5-R8.
Wagner, J., et al., “Neuropharmacology of Endogenous Opioid Peptides,” Psychopharmacology: The Fourth Generation of Progress, 1995: 519-529.
Weber, S.J., et al., “Distribution and Analgesia of [3H][D-PEN2, D-PEN5] Enkephalin and Two Halogenated Analogs after Intravenous Administration,” J. Pharm. Exper. Ther., 1991, 259: 1109-1112.
Weber, S.J., et al., “Whole Body and Brain Distribution of [3H]Cyclic [D-PEN2, D-PEN5] Enkephalin after Intraperitoneal, Intravenous, Oral and Subcutaneous Administration,” J. Pharm. Exper. Ther., 1992, 263: 1308-1316.
Alyautdin, R.N., “Delivery of Loperamide Across the Blood-Brain Barrier with Polysorbate 80-Coated Polybutylcyanoacrylate Nanoparticles,” Pharm. Res. J., 1997, 15: 325-328.
Aoshima, M. et al., “N4-Behenoyl-1-β-D-Arabinofuranosylcytosine as a Potential New Antitumor Agent,” Cancer Research, 1977, 37:2481-2486.
Banting, R. G., et al., “Pancreatic Extracts in the Treatment of Diabetes Mellitus,” The Canadian Med. Assoc. J. 1922, 12: 141-146.
Baker, D. C. et al., “Prodrugs of 9-β-D-Arabinofuranosyladenine. 1.
Anderson Jr. Wes
Ansari Adam M.
Ekwuribe Nnochiri N.
Price Christopher H.
Rhadakrishnan Balasingam
Barrett William A.
Celsa Bennett
Moore & Van Allen PLLC
Nobex Corporation
LandOfFree
Methods for delivering therapeutics across blood-barrier and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for delivering therapeutics across blood-barrier and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for delivering therapeutics across blood-barrier and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3448672